Sei in: Home > Personale > Prof. Enrico GIRAUDO

Prof. Enrico GIRAUDO

Professore Associato

Contatti

  • 0119933279 - 0116706863
  • 0119933524
  • Transgenic Mouse Models Laboratory
    Candiolo Cancer Institute – FPO, IRCCS,
    Department of Science and Drug Technology,
    University of Torino
    Strada Prov. 142 Km.3,95,
    Cap 10060 - Candiolo (To)
    Lab webpage: http://www.ircc.it/irccit/?q=Transgenic-Mouse-Models
  • http://www.dstf.unito.it/persone/enrico.giraudo
  • VCard contatti
  • QRcode contatti

Presso

Curriculum vitae

Pubblicazioni selezionate

Impact factor (IF) and Times of Citation according to the ISI Web of Science and the SCOPUS citation database.

Up to July 2017, Enrico Giraudo has an h-index of 24 (h-index of 27 and a total of 3898 citations, based on google scholar); a number of total citations of the global scientific production of 2877, total citations number normalized (academic age) of 133,8;  a total Impact Factor (IF) of 310,360  and an Average IF per paper of 9.129. He's co-author in a book chapter; he has been invited for lecture or seminar up to 20 talks and he presented 47 abstract and proceedings to national and international congress. Moreover Giraudo has been co-organizer of an international workshop in Leiden, The Netherlands.

1) Zoi Diamantopoulou, Maud-Emmanuelle Gilles, Maha Sader, Mélissande Cossutta, Benoit Vallée, Claire Houppe, Damien Habert, Blandine Brissault, Eric Leroy, Federica Maione, Enrico Giraudo, Damien Destouches, Jacques Penelle, José Courty1, and Ilaria Cascone.  Multivalent cationic pseudopeptide polyplexes as a tool for cancer therapy. Oncotarget. 2017; 8:90108-90122. IF: 5.168

2) Regano D, Visintin A, Clapero F, Bussolino F, Valdembri D, Maione F, Serini G, *Giraudo ESema3F (Semaphorin 3F) Selectively Drives an Extraembryonic Proangiogenic Program. Arterioscler Thromb Vasc Biol. 2017 Jul 20. pii: ATVBAHA.117.308226. doi: 10.1161/ATVBAHA.117.308226. [Epub ahead of print]. *Corresponding author and last author. IF: 6,607;

3 ) Gilles ME, Maione F, Cossutta M, Carpentier G, Caruana L, Di Maria S, Houppe C, Destouches D, Shchors K, Prochasson C, Mongelard F, Lamba S, Bardelli A, Bouvet P, Couvelard A, Courty J, Giraudo E*, Cascone I*. Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature. Cancer Res. Cancer Res. 2016 Dec 15;76(24):7181-7193.  10.1158/0008-5472.CAN-16-0300. *Co-Corresponding author and Co-last authorIF: 9,284;

4) Avanzato D, Genova T, Fiorio Pla A, Bernardini M, Bianco S, Bussolati B, Mancardi D, Giraudo E, Maione F, Cassoni P, Castellano I, Munaron L.  Activation of P2X7 and P2Y11 purinergic receptors inhibits migration and normalizes tumor-derived endothelial cells via cAMP signaling. Sci Rep2016 Sep 2;6:32602. IF: 5,578.

5) Valdembri D, Regano D, Maione F, Giraudo E*, Serini G. Class 3 semaphorins in cardiovascular development. Cell adh migr2016 Jul 20:1-11. [Epub ahead of print]. *Co-Corresponding author and Co-last authorIF: 4,505.

6) Leuci V, Maione F, Rotolo R, Giraudo E, Sassi F, Migliardi G, Todorovic M, Gammaitoni L, Mesiano G, Giraudo L, Luraghi P, Leone F, Bussolino F, Grignani G, Aglietta M, Trusolino L, Bertotti A, Sangiolo D. Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. J Transl Med. 2016 May 5;14(1):119. doi: 10.1186/s12967-016-0872-2. IF: 3.930Time cited: 1.

7) Federica Maione, Simonetta Oliaro-Bosso, Claudia Meda, Federica Di Nicolantonio, Federico Bussolino, Gianni Balliano, *Franca Viola and Enrico Giraudo*. The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination.  Sci. Rep2015March 12; 5, 9054; DOI:10.1038/srep09054. *Corresponding authorIF=5,578.  Time cited 2.

7) Federica Maione and Enrico Giraudo*. Tumor Angiogenesis: Methods to Analyze Tumor Vasculature and Vessel Normalization in Mouse Models of Cancer. Methods Mol. Cell. Biol., 2015. vol. 1267:349-65. doi: 10.1007/978-1-4939-2297-0_17. *Corresponding authorIF=1,290Time cited 1.

9) Patella F, Schug ZT, Persi E, Neilson LJ, Erami Z, Avanzato D, Maione F, Hernandez-Fernaud JR, Mackay G, Zheng L, Reid S, Frezza C, Giraudo E, Fiorio Pla A, Anderson K, Ruppin E, Gottlieb E, anivan S. Proteomics-based metabolic modelling reveals that fatty acid oxidation controls endothelial cell permeability. Mol Cell Proteomics2015; Jan 8. pii: mcp.M114.045575. Epub ahead of print. IF=7,254Time cited: 10.

10) Corà D, Astanina E, Giraudo E, Bussolino F. Semaphorins in cardiovascular medicine. Trends Mol Med2014. Oct;20(10):589-98. pii: S1471-4914(14)00121. IF: 10,110; Time cited: 2

11) Valetti S, Maione F, Mura S, Stella B, Desmaële D, Noiray M, Vergnaud J, Vauthier C, Cattel L,Giraudo E, Couvreur P. Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor. J Control Release2014, 192: 29-39. IF: 7.261, Time cited 14.

12) Bussolino F, Giraudo E, Serini G. Class 3 semaphorin in angiogenesis and lymphangiogenesis. Chem Immunol Allergy2014;99:71-88. IF: 5,59Time cited: 6

13) Zanivan S, Maione F, Hein MY, Hernández-Fernaud JR, Ostasiewicz P, Giraudo E, Mann M. SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers. Mol Cell Proteomics2013 Dec;12(12):3599-611. IF: 7.254Time cited: 10

14) Gu C, Giraudo E*. The role of semaphorins and their receptors in vascular development and cancer. Exp Cell Res2013 May 15;319(9):1306-16. *Corresponding author. IF: 3,372Times cited: 42

 15) Guido Serini, Federico Bussolino, Federica Maione and Enrico Giraudo*. Class 3 semaphorins: physiological vascular normalizing agents for anti-cancer therapy. J. Intern. Med. 2013 Feb;273(2):138-55. . * Corresponding author. IF: 5,785; Times cited: 14.

 16) Carrer A, Moimas S, Zacchigna S, Pattarini L, Zentilin L, Ruozzi G, Mano M, Sinigaglia M, Maione F, Serini G, Giraudo E, Bussolino F, Giacca M. Neuropilin-1 identifies a subset of bone marrow Gr1- monocytes that can induce tumor vessel normalization and inhibit tumor growth. Cancer Res2012, Dec 15; 72:6371-6381.  IF: 9,284Times cited: 24.

 17) Napione L, Strasly M, Meda C, Mitola S, Alvaro M, Doronzo G, Marchiò S, Giraudo E, Primo L, Arese M, Bussolino F.  IL-12-dependent innate immunity arrests endothelial cells in G0-G1 phase by a p21(Cip1/Waf1)-mediated mechanism. Angiogenesis2012 Dec;15(4):713-25. IF: 4.410Times cited: 1.

 18) Federica Maione, Stefania Capano, Donatella Regano, Lorena Zentilin, Mauro Giacca, Oriol Casanovas, Federico Bussolino, Guido Serini, and Enrico Giraudo1. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J. Clin. Invest. (2012), May 1;122(5):1832-48. Head of print on April 9, 2012. Corresponding author. IF: 13.765; Times cited: 72.

 19) Claudia Meda, Fabiola Molla, Maria De Pizzol, Donatella Regano, Federica Maione, Stefania Capano, Massimo Locati, Alberto Mantovani, Roberto Latini, Federico Bussolinoand Enrico Giraudo1. Sema4A exerts a pro-angiogenic effect by enhancing VEGF-A expression in macrophages. J. Immunol. (2012), Apr 15; 188 (8); 4081-92. Epub 2012 Mar 21. Corresponding author. IF: 5.362; Times cited: 22.

 20) Casazza A, Kigel B, Maione F, Capparuccia L, Kessler O, Giraudo E, Mazzone M, Neufeld G, Tamagnone L. Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform. EMBO Mol Med. (2012), Mar;4(3):234-50, Epub 2012 Jan 13. IF: 8.254; Times cited: 38.

 21) Ribba B, Watkin E, Tod M, Girard P, Grenier E, You B, Giraudo E, Freyer G. A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. Eur J Cancer. (2011).  Feb;47(3):479-90. IF: 4.819; Times cited: 22.

 22) Primo L, Seano G, Roca C, Maione F, Gagliardi PA, Sessa R, Martinelli M, Giraudo E, di Blasio L, Bussolino F. Increased expression of α6 integrin in endothelial cells unveils a proangiogenic role for basement membrane. Cancer Res. (2010) Jul; 70(14):5759-69. IF: 9.284; Times cited: 27.

 23) Federica Maione, Fabiola Molla, Roberto Latini, Lorena Zentilin, Mauro Giacca, Claudia Meda, Giorgio Seano, Guido Serini, Federico Bussolino and Enrico Giraudo1. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J. Clin. Invest. (2009); Nov;119: 3356-72. Corresponding author. IF: 13.765; Times cited: 100.

 24) Oliaro-Bosso S, Calcio Gaudino E, Mantegna S, Giraudo E, Meda C, Viola F, Cravotto G. Regulation of HMGCoA Reductase Activity by Policosanol and Octacosadienol, a New Synthetic Analogue of Octacosanol. Lipids. (2009); Oct 44 (10):907-916. IF: 2.353; Times cited: 28.

 25) Serini G, Maione F, Giraudo E, Bussolino F. Semaphorins and tumor angiogenesis. Angiogenesis, (2009); May 12(2):195. IF: 4.41; Times cited: 33.

 26) Francesca Orso, Elisa Penna, Daniela Cimino, Elena Astanina, Federica Maione, Donatella Valdembri, Enrico Giraudo, Guido Serini, Piero Sismondi, Michele De Bortoli and Daniela Taverna. AP-2a and AP-2g Regulate Epithelial Tumor Progression via Specific Genetic Programs. FASEB J, (2008). Aug 22(8):2702-14. IF: 5.480; Times cited: 43.

 27) Lianglin Zhang, Enrico Giraudo, Jason A. Hoffman, Douglas Hanahan and Erkki Ruoslahti. Lymphatic Zip Codes in Tumors and Premalignant Lesions. Cancer Res (2006); Jun 1; 66(11):5696-706. IF: 9.284Times cited: 47.

 28) Giraudo E.1 and Hanahan D. Zoledronic acid inhibit angiogenesis and impairs tumorigenesis in a mouse model of cervical carcinogenesis. Haematologica Reports (2006) March; 2(3):39-41. Corresponding author. Times cited: 2.

 29) Dylan Daniel, Christopher Chiu, Enrico Giraudo, Masahiro Inoue, Lee A. Mizzen, N. Randall Chu and Douglas Hanahan. CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res. (2005); Mar 1, 65(5):2018-25. IF: 9.284; Times cited: 56.

 30) Giraudo E., Inoue M., and Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis". J. Clin. Invest. (2004); Sep 1, 114(5):623-33. IF: 13.765; Times cited: 429.

 31) Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, Greenbaum DC, Hager JH, Bogyo M, Hanahan DCathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. (2004); May, 5(5):443-53. IF: 23.893; Times cited: 325. 

 32) Hoffman JA*, Giraudo E*1, Singh M, Zhang L, Inoue M, Porkka K, Hanahan D, Ruoslahti E. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell. (2003); Nov, 4(5):383-91.*1First author co-autorship.  IF: 23.893; Times cited: 113. 

 33) Ilaria Cascone *, Enrico Giraudo *, Francesca Caccavari, Lucia Napione, Elisa Bertotti, John G. Collard, Guido Serini and Federico Bussolino. Temporal and spatial modulation of  Rho GTPases during in vitro formation of capillary vascular network. Adherens junctions and myosin light chain as targets of Rac1 and RhoA. J Biol Chem. (2003); Dec, 278(50):50702-13. * 1First author co-autorship.           IF: 4.600; Times cited: 47. 

 34) Cascone I, Audero E, Giraudo E, Napione L, Maniero F, Philips MR, Collard JG, Serini G, Bussolino F.. Tie-2 - dependent activation of RhoA and Rac1 participates in endothelial cell motility triggered by angiopoietin-1. Blood. (2003); Oct , 102(7):2482-90. IF: 9.775; Times cited: 38. 

 35) Serini G*, Ambrosi D*, Giraudo E*1 Gamba A*, Preziosi L, Bussolino F. "Modeling the early stages of vascular network assembly". EMBO J. (2003); Apr, 22(8):1771-9. *1First author co-autorship.IF: 10.748; Times cited: 155. 

 36) Corallini A, Possati L, Trabanelli C, Giraudo E, Rocchetti R, Talevi S, Caputo A, Bussolino F, Barbanti-Brodano G.. Tumor-host interaction mediates the regression of BK virus-induced vascular tumors in mice: involvement of transforming growth factor-b1. Carcinogenesis. (2003); 24(9):1435-44. IF: 5.266; Times cited: 5

37) Gamba A, Ambrosi D, Coniglio A, de Candia A, Di Talia S, Giraudo E, Serini G, Preziosi L, Bussolino F. Percolation, morphogenesis, and burgers dynamics in blood vessels formation. Phys Rev Lett. (2003) Mar 21;90(11):118101. Epub 2003 Mar 17. IF: 7.728Times cited: 102.

 38) Del Sorbo, M. Arese, Giraudo E., M. Tizzani, L. Biancone, F.Bussolino, G.Camussi. "Tat-induced platelet-activating factor synthesis contributes to the angiogenic effect of HIV-1 Tat. Eur J Immunol(2001) Feb;31(2):376-383. IF: 4.518; Times cited: 20.

 39) Cutrupi S, Baldanzi G, Gramaglia D, Maffe A, Schaap D, Giraudo E, van Blitterswijk W, Bussolino F, Comoglio PM, and Graziani A. "Src-mediated activation of alpha-diacylglycerol kinase is required for hepatocyte growth factor-induced cell motility". EMBO J. (2000) Sep 1;19(17):4614-22. IF: 10.748; Times cited: 67.

 40) Giraudo E.,. Primo L,. Audero E,. Gerber HP, Koolwijk P,. Soker S , Klagsbrun M Ferrara N, and. Bussolino F. "Tumor necrosis factor-a regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells". J. Biol. Chem., (1998) Aug 21;273(34):22128-35. IF: 4.600; Times cited: 183.

 41) A. Albini, R. Soldi, D. Giunciuglio, E. Giraudo, R. Benelli, L. Primo, D. Noonan, M. Salio, G. Camussi, W. Rockl and F. Bussolino. "The angiogenesis induced by HIV-1 Tat protein is mediated by the flk-1/KDR receptor on vascular endothelial cells". Nature Med. (1996) Dec;2(12):1371-75. IF: 28.054; Times cited: 286.

 42) Giraudo E., M. Arese, C Toniatti, M Stransly, L Primo, A Mantovani, G Ciliberto and F. Bussolino. "Interleukin-6 is an in vitro and in vivo autocrine growth factor for middle T antigen-transformed endothelial cells." J. Immunol , (1996) Sep 15;157(6):2618-23. IF: 5.362; Times cited: 48.

 42) F. Silvagno, A. Follenzi, M. Arese, M. Prat, E. Giraudo, G. Gaudino, G. Camussi, P. M. Comoglio, F. Bussolino. "In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis". Arterioscler. Thromb. Vasc. Biol. (1995) Nov;15(11):1857-65. IF: 5.533; Times cited: 80.

 

Book chapters

F. Bussolino, Arese M, Audero E, Giraudo E., Marchiò S, Mitola S, Primo L, Serini G. (2003). Biological aspects of tumour angiogenesis. In: PREZIOSI L. Cancer Modelling and simulation. (pp. 1-22). LONDON: Chapan & Hall /CRC (UNITED KINGDOM).

  • Invited lectures

1. Lausanne, Svitzerland, October 6th 2015. ISREC/SCCL special seminar. Seminario dal titolo: "Macrophage "re-education" induced by zoledronic acid impairs tumor angiogenesis and metastatic dissemination in a mouse model of spontaneous cervical cancer".

 

2. S. Diego, CA, USA, aprile 5-9, 2014. 105rd AACR Annual Meeting 2014. Symposium "Tumor angiogenesis". Seminario dal titolo: "Zoledronic acid overcomes the resistance to the anti-angiogenic therapy and normalizes tumor vessels by switching from a M2- to a M1-like macrophages phenotype in a mouse model of spontaneous cervical cancer".

 

3. Amsterdam, The Netherlands 12-14 Marzo 2014. 5th International Meeting on Angiogenesis, VU University Medical Center. Seminario dal titolo: "Zoledronic acid normalizes tumor vessels and blocks metastasis formation by skewing macrophages from a M2 to an M1-like phenotype in a mouse model of spontaneous cervical cancer.

 

4. Pontignano, Siena, Italia, 13-15 maggio 2013. Angiogenesi: basi molecolari e implicazioni terapeutiche IV. Seminario dal titolo: " Sema 3A: a new tool to normalize the tumor vasculature and to impair metastasi dissemination".

 

5. Lausanne, Switzerland, 5 Febbraio 2013. Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences. Swiss Federal Institute of Technology Lausanne (EPFL). Lecture dal titolo " Semaphorin 3A: a new tool to "normalize" the tumor microenvironment and to block metastasis dissemination".

 

6. Trieste, Italia, Novembre 29 2012. International Centre for Genetic Engineering and Biotechnology (ICGEB). Seminario dal titolo: "Semaphorin 3A: a new tool to normalize the tumor vasculature and to block metastasi dissemination".

 

7. Chicago, Illinois, USA, 31 marzo- 4 aprile, 2012. 103rd AACR Annual Meeting 2012. Major Symposium "Vascular Reprogramming to improve Clinical Outcome". Seminario dal titolo: "Targeting semaphorin 3A: a new tool to normalize tumor vasculature and to overcome the evasive resistance to antiangiogenic therapy".   

 

8. Lausanne, Switzerland, 7-10 settembre 2011. SREC Symposium 2011 Hallmarks and Horizons of Cancer. Seminario dal titolo: "Semaphorin 3A blocks cancer invasiveness and metastases dissemination induced by the anti-angiogenic therapy by overcoming tumor hypoxia".

 

9. Pontignano, Italia, 10-12 maggio 2010. Workshop SIICA, "Angiogenesi: basi molecolari ed implicazioni terapeutiche III". Seminario dal titolo: "In vivo targeting semaphorins: new tools to control tumor angiogenesis and tumor invasiveness".

 

10. Lausanne, Switzerland, 2 Febbraio 2010. Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences. Swiss Federal Institute of Technology Lausanne (EPFL). Lecture dal titolo: "In vivo targeting semaphorins: new tools to control tumor angiogenesis".

 

11. Roma, Italia, 15-16 gennaio 2010. International Conference "in memory of Judah Folkman "Update on angiogenesis: translational research". Seminario dal titolo: "In vivo targeting semaphorins: new tools to control tumour angiogenesis".

 

12. Parigi, Francia, 27 aprile 2009. Marie Curie Institute, Parigi; Lecture dal titolo: " In vivo targeting semaphorins: new tools to control tumor angiogenesis."

 

13. Roma, Italia, 24 gennaio 2009. "Update on Angiogenesis: One year from the departure of Judah Folkman". Seminario dal titolo: "Semaphorins and tumor angiogenesis".

 

14. San Francisco, CA, USA, 12-15 gennaio 2009. "Mouse Models of Cancer", AACR special conference in cancer Research. Seminario dal titolo: "Semaphorin 3A Regulates Angiogenesis and Tumor Progression in Mouse Models of Tumorigenesis".

 

15. Riccione, Italia 26-28 settembre 2007. Congresso SIB2007. "Cellular Biochemistry". Seminario dal titolo: "Role of class 3 semaphorins in tumor angiogenesis in transgenic mouse models of carcinogenesis".

 

16. Rod Island, Newport, USA, 19-24 Agosto 2007. Salve Regina University, Gordon Conference on Angiogenesis. Seminario dal titolo: "Role of class 3 semaphorins in tumor angiogenesis in transgenic mouse models of pancreatic and cervical carcinogenesis".

 

17. Riccione, Italia 28-30 settembre 2006. Congresso SIB2007. "Cellular Biochemistry". Seminario dal titolo: "Molecular changes in lymphatic vessels during tumor progression"

 

18. Davos, Switzerland, 22 - 25 marzo, 2006. Eighth and Valedictory Workshop on Bisphosphonates From the Laboratory to the Patient. Seminario dal titolo: "Anti-angiogenic effects of bisphosphonates".

 

19. Cervo Ligure, Italy, 6-8 ottobre 2005. Cervo Preclinical Working Conference (CPWC). Seminario dal titolo: "Aminobisphosphonates inhibit angiogenesis and impairs carcinogenesis in a mouse model of cervical carcinogenesis".

 

20. Milano, Italia, 11-14 marzo, 2004. "First IEO-IFOM meeting on cancer". Seminario dal titolo: "A bisphosphonate inhibits angiogenesis and impairs cervical carcinogenesis by targeting MMP-9 activity and its expression in infiltrating macrophages".  

Organized Meetings, conferences and workshop

 Workshop at Lorenz Center, October 4-8th 2010, Leiden, The Netherlands. Scientific organizer of the workshop: "Modelling angiogenesis: joining cells, maths and computers".

Corsi di insegnamento

Temi di ricerca

  • Research projects
  • Publications
  • Invited lectures
  • International cooperations
  • National cooperations

Research topic

The laboratory is focused on discovering new targets and molecular mechanisms for anti-angiogenic therapies.

Background

Angiogenesis is required for invasive tumor growth and metastasis. Despite the development of innovative anti-angiogenic strategies, clinical trials have not replicated the results observed from preclinical models and resistance to anti-VEGF therapy has been recently observed in both preclinical and clinical trials. Hence, there is a need to identify new angiogenic modulators and mechanisms. Axon guidance cues, such as semaphorins and their receptors have been firstly identified in determining the proper neural connection during brain development. Recently, it has been demonstrated that they are involved in tumor angiogenesis and growth. However, the orchestrated roles played by these molecules and how they act in tumor vascularization and tumor invasion are essentially unknown.

Achievements

By employing transgenic mouse models of spontaneous pancreatic (RipTag2), cervical (K14-HPV16/E2) and skin (K14-HPV16) carcinogenesis we have found that Sema3A is an endogenous angiogenesis inhibitor, lost during tumor progression. Re-expression of Sema3As in RipTag2 tumors using AAV8 delivery system inhibited angiogenesis, cancer growth, normalized tumor vessels and restored tumor normoxia. We have more recently shown that the treatment of RIP-Tag2 and cervical carcinomas (HPV16/E2) mouse models with AAV8-Sema3A, by improving cancer tissue oxygenation and extending the normalization window, counteracted Sunitinib- and DC101 (anti-VEGFR2 antibody)- induced evasive resistance to the therapy by inhibiting tumor metastasis and, consequently, enhancing the survival. Importantly, Sema3A, by normalizing tumor vessels, efficiently improved the delivery of chemotherapeutic drugs to the tumors.

 
Goals
We plan (i) to employ Sema3A super-agonists mutants as a new compound to overcome the evasive resistance to the anti-angiogenic therapies, to halt metastasis formation and to normalize tumor vessels; (ii) to assess the efficacy of combining Sema3s or other axon guidance cues delivery with conventional anti-angiogenic drugs to block metastases  dissemination using different mouse models of cancer; (iii) to identify the mechanisms by which Semas, their receptors and other axon guidance cues regulate “stroma” normalization, tumor invasiveness and metastases formation.

 

 

Gruppi di ricerca

Progetti di ricerca

Ricevimento studenti

Tutti i giorni previo appuntamento
Ultimo aggiornamento: 15/11/2017 23:05
Campusnet Unito
Non cliccare qui!